End looms for Cassava's simufilam in Alzheimer's disease
5 days ago · In the 804-subject study, simufilam-treated patients saw a 2.8-point change from baseline after 52 weeks on the ADAS-Cog12 cognition scale, while the placebo group saw a 3.2-point change, which ...
Alzheimer Agent Simufilam Fails Phase 3, Lamotrigine Trial in DLB ...
1 day ago · Welcome to this special edition of Neurology News Network. I'm Marco Meglio. New topline data from the phase 3 ReThink-ALZ study (NCT04994483) showed that treatment with investigational simufilam (Cassava Sciences), a small molecule agent targeting an altered form of filamen A (FLNA), did not meet each of its pre-specified co-primary, secondary, and exploratory biomarker end points in patients ...
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary …
5 days ago · Simufilam, an investigational oral, small molecule drug candidate that targets the filamin A protein, is under evaluation for the potential treatment of Alzheimer's disease. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.
Alzheimer Agent Simufilam Fails to Meet Primary End Point in …
5 days ago · New topline data from the phase 3 ReThink-ALZ study (NCT04994483) showed that treatment with investigational simufilam (Cassava Sciences), a small molecule agent targeting an altered form of filamen A (FLNA), did not meet each of its pre-specified co-primary, secondary, and exploratory biomarker end points in patients with mild-to-moderate Alzheimer disease (AD).
A Controversial Alzheimer's Drug Has Gone Down in Flames
4 days ago · Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by allegations of poorly done and fraudulent research.
Simufilam found safe in review of ongoing Alzheimer's clinical trials
Sep 26, 2024 · After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing the oral therapy simufilam in people with Alzheimer’s disease.
Topline results of Phase 3 studies of simufilam for Alzheimer's...
Feb 8, 2024 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.
Simufilam aids cognition in 47% of Alzheimer's patients in Phase 2...
Mar 14, 2023 · Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.
No Decline in Cognition Scores in Patients with Mild Alzheimer's ...
AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the proposed treatment of …
Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report
Oct 14, 2023 · In August 2021, two scientists filed a citizen’s petition with the Food and Drug Administration in which they described “grave concerns about the quality and integrity” of the research that...
- Some results have been removed